Bay­er gets green light to sell long-act­ing he­mo­phil­ia A ther­a­py as Roche mus­cles in with Hem­li­bra

Adding an­oth­er com­mer­cial prod­uct to its he­mo­phil­ia port­fo­lio, Bay­er has re­ceived FDA ap­proval for its long-act­ing re­com­bi­nant Fac­tor VI­II re­place­ment ther­a­py for he­mo­phil­ia A …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER